1.575
Schlusskurs vom Vortag:
$1.61
Offen:
$1.59
24-Stunden-Volumen:
47,340
Relative Volume:
0.02
Marktkapitalisierung:
$81.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.44M
KGV:
-0.8378
EPS:
-1.88
Netto-Cashflow:
$-66.75M
1W Leistung:
+8.92%
1M Leistung:
-7.20%
6M Leistung:
-47.37%
1J Leistung:
-69.31%
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Firmenname
Black Diamond Therapeutics Inc
Sektor
Branche
Telefon
617-417-5868
Adresse
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Vergleichen Sie BDTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BDTX
Black Diamond Therapeutics Inc
|
1.575 | 81.61M | 0 | -82.44M | -66.75M | -1.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
487.58 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
592.81 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
602.10 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.27 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.67 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-31 | Eingeleitet | Raymond James | Outperform |
2023-07-14 | Eingeleitet | Piper Sandler | Overweight |
2023-06-30 | Hochstufung | Stifel | Hold → Buy |
2023-06-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2023-06-27 | Hochstufung | Wedbush | Neutral → Outperform |
2022-03-29 | Herabstufung | Wedbush | Outperform → Neutral |
2022-03-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2021-09-30 | Eingeleitet | Stifel | Hold |
2021-01-07 | Eingeleitet | Wedbush | Outperform |
2020-11-24 | Eingeleitet | Berenberg | Buy |
2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
2020-02-24 | Eingeleitet | Canaccord Genuity | Buy |
2020-02-24 | Eingeleitet | Cowen | Outperform |
2020-02-24 | Eingeleitet | JP Morgan | Overweight |
2020-02-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
Black Diamond Therapeutics Inc (BDTX) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Head-To-Head Contrast: Avalon GloboCare (NASDAQ:ALBT) and Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Wellington Management Group LLP - Defense World
Raymond James Financial Inc. Purchases New Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond stock hits 52-week low at $1.42 amid challenges - Investing.com India
Black Diamond stock hits 52-week low at $1.42 amid challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc [BDTX] stock for 11,997,749 USD was sold by BIOTECH GROWTH N V - knoxdaily.com
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Holdings Raised by Intech Investment Management LLC - The AM Reporter
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Therapeutics Surge: Savvy Move or Bubble? - timothysykes.com
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com India
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):